解放军医学杂志2025，Vol.50Issue(6)：672-678,7.DOI:10.11855/j.issn.0577-7402.1065.2025.0123
免疫检查点分子VISTA在血液系统肿瘤中的研究进展
Research progress of an immune checkpoint molecule VISTA in hematological tumors
摘要
Abstract
Research on immune checkpoints such as programmed death protein-1(PD-1)and cytotoxic T lymphocyte antigen-4(CTLA-4)has provided new directions for tumor treatment.V-domain immunoglobulin suppressor of T-cell activation(VISTA)is an emerging immune checkpoint within the B7 family.Functioning as both a ligand and a receptor,VISTA is an inhibitory immune checkpoint molecule expressed in tumor cells,myeloid cells and T lymphocytes.It plays a crucial role in regulating autoimmunity,inflammatory response and tumor immunity.The non-redundant interactions between VISTA and other immune checkpoints,such as PD-1,may offer new therapeutic strategies and serve as a new target for overcoming immunotherapy resistance.This review summarizes the recent research progress on VISTA in hematological tumors,aiming to provide new insights into its application in the treatment of these malignancies.关键词
T细胞活化V结构域Ig抑制因子/免疫检查点/血液系统肿瘤/免疫治疗Key words
V-domain immunoglobulin suppressor of T-cell activation/immune checkpoint/hematological tumor/immunotherapy分类
医药卫生引用本文复制引用
汤子君,郑涵雪,熊皓,张连生,李莉娟..免疫检查点分子VISTA在血液系统肿瘤中的研究进展[J].解放军医学杂志,2025,50(6):672-678,7.基金项目
This work was supported by the National Natural Science Foundation of China(82360029),and the Gansu Provincial Science and Technology Project(21JR7RA435,21JR7RA394,21JR11RA104) 国家自然科学基金(82360029) （82360029）
甘肃省科技计划项目(21JR7RA435,21JR7RA394,21JR11RA104) （21JR7RA435,21JR7RA394,21JR11RA104）
